Exploring the Potential of JAK1/2 Inhibitor Ruxolitinib with Reduced Intensity Hematopoietic Cell Transplantation (HCT) for Myelofibrosis: Stage I Results of a Prospective Trial Conducted through the Myeloproliferative Disorders - Research Consortium (MPD-RC)Vikas Gupta, Ronald Hoffman, Heidi Kosiorek et al.|Blood|2016Cited by 2
Alimentación enteral hipercalórica en ninos con desnutrición severaZiomara Reeves, Cristina Llusa, Guillermo Costaguta et al.|Unknown|1993Cited by 0